The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibitor in Patients With Elevated Risk) trial found that treatment with PCSK9-inhibitor in patients with ASCVD and LDL cholesterol ≥ 70 mg/dL despite statin therapy was linked with a greater absolute risk reduction in those with hsCRP > 3 mg/L compared to those with lower hsCRP [34], and the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) trial identified individuals who benefited from intensified statin therapy by a hsCRP ≥2 mg/L in stroke prevention [35]. This evidence concerns the gene PCSK9 and stroke disorder.